Peptides for sleep: what the evidence actually supports

What's this video probably claiming?

Based on the hashtags and caption, @aestheticmaxx1 is almost certainly running through a list of peptides, likely ipamorelin, CJC-1295, MK-677, and possibly selank or DSIP (delta sleep-inducing peptide), pitching them as tools to improve sleep quality, growth hormone release during sleep, and possibly cognitive function given the #iq hashtag. The "looksmax" and "sleepmax" framing suggests this is aimed at young men optimizing appearance and performance, where deep sleep is framed as the unlock for muscle recovery and fat loss. These peptides are being positioned as superior to melatonin or other conventional sleep aids. The implicit message is almost always the same in this genre: pharma-grade results without the pharmaceutical label. That framing deserves serious scrutiny.

What does the science actually show?

The most studied peptides in this context are growth hormone secretagogues. Ipamorelin and CJC-1295 do stimulate pulsatile GH release, and GH naturally peaks during slow-wave sleep. A 2006 study by Ionescu and Frohman in Endocrine Reviews confirmed that GH secretagogues amplify overnight GH pulses, but the clinical sleep architecture data is thin. MK-677, an oral ghrelin mimetic, has more strong trial data. In a randomized crossover trial by Copinschi et al. (1997) in Sleep, MK-677 increased REM sleep by roughly 50% and stage 4 sleep by 20% in healthy elderly subjects. DSIP has rodent data but almost no quality human trials. Selank shows anxiolytic properties in Russian literature, mostly preclinical. The honest read: one peptide has decent human sleep data, the rest are extrapolations from GH physiology or animal models.

Where does the social media noise diverge from clinical reality?

The gap here is significant. Creators in the sleepmax space routinely conflate GH secretion with sleep quality improvement, which are not the same thing. Releasing more GH overnight does not automatically mean better sleep architecture, more recovery, or improved cognition the next day. The Copinschi MK-677 trial used elderly subjects, and the effect sizes have not been replicated consistently in young, healthy populations. More critically, MK-677 chronically elevates ghrelin, which increases appetite and can cause insulin resistance over time. A 2008 study by Nass et al. in Annals of Internal Medicine found that two years of MK-677 in elderly adults produced meaningful increases in fasting glucose. Ipamorelin and CJC-1295 are compounded peptides with no FDA approval, inconsistent purity across suppliers, and zero long-term safety trials. Framing these as "best peptides for sleep" skips over that entire risk picture.

What should you actually know?

If sleep optimization is actually your goal, the intervention with the strongest evidence base is still cognitive behavioral therapy for insomnia (CBT-I), which outperforms sleep medication in long-term outcomes per a meta-analysis by Mitchell et al. (2012) in BMJ. Within peptide science, MK-677 is the only compound with published human sleep data worth citing, and even that data has limitations around population generalizability and metabolic side effects. Selank and DSIP are interesting preclinically but calling them "best peptides for sleep" in 2025 is a marketing claim, not a scientific one. Anyone considering peptides for sleep should be working with a licensed clinician who can assess baseline GH axis function, not following a TikTok list. The regulatory status of these compounds matters too. Most are not approved for this use, and sourcing and dosing carry real risks that vanish from the conversation in 60-second videos.